Teomete, M. Et Al. 2024. Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review). Oncology Letters , vol.27, no.4 .

Teomete, M., ÇABUK, D., Korkmaz, T., Seber, S., Ozturk, O. F., Aver, B., ... Karaalp, A.(2024). Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review). Oncology Letters , vol.27, no.4.

Teomete, Mehmet Et Al. "Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)," Oncology Letters , vol.27, no.4, 2024

Teomete, Mehmet Et Al. "Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)." Oncology Letters , vol.27, no.4, 2024

Teomete, M. Et Al. (2024) . "Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)." Oncology Letters , vol.27, no.4.

@article{article, author={Mehmet Teomete Et Al. }, title={Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)}, journal={Oncology Letters}, year=2024}